Cargando…

A machine learning-based algorithm to eliminate breast and axillary surgery in patients with breast cancer and pathological complete response after neoadjuvant chemotherapy

Detalles Bibliográficos
Autores principales:	de Nonneville, Alexandre, Boudin, Laurys, Houvenaeghel, Gilles, Gonçalves, Anthony, Bertucci, François
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Editorial Commentary \| Data Sciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632564/ https://www.ncbi.nlm.nih.gov/pubmed/37970604 http://dx.doi.org/10.21037/atm-23-689

Ejemplares similares

Prognostic and Predictive Value of LIV1 Expression in Early Breast Cancer and by Molecular Subtype
por: de Nonneville, Alexandre, et al.
Publicado: (2023)

CISH Expression Is Associated with Metastasis-Free Interval in Triple-Negative Breast Cancer and Refines the Prognostic Value of PDL1 Expression
por: Boudin, Laurys, et al.
Publicado: (2022)

Association of higher axillary pathologic complete response rate with breast pathologic complete response after neoadjuvant chemotherapy
por: Zhu, Jiujun, et al.
Publicado: (2020)

Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer
por: Bertucci, François, et al.
Publicado: (2023)

Neoadjuvant Chemotherapy for Breast Cancer: Evolution of Clinical Practice in a French Cancer Center Over 16 Years and Pathologic Response Rates According to Tumor Subtypes and Clinical Tumor Size: Retrospective Cohort Study
por: Houvenaeghel, Gilles, et al.
Publicado: (2022)

Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer
por: Sabatier, Renaud, et al.
Publicado: (2019)

Discrepancy of Breast and Axillary Pathologic Complete Response and Outcomes in Different Subtypes of Node-positive Breast Cancer after Neoadjuvant Chemotherapy
por: Chen, Shin-Cheh, et al.
Publicado: (2021)

Prognostic impact of hormone receptor- and HER2-defined subtypes in inflammatory breast cancer treated with high-dose chemotherapy: a retrospective study
por: Boudin, Laurys, et al.
Publicado: (2016)

Prognostic Nomogram for Prediction of Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy in Cytologically Proven Node-Positive Breast Cancer
por: Kim, Jee Ye, et al.
Publicado: (2015)

Sentinel Lymph Node Biopsy in Breast Cancer Patients With Pathological Complete Response in the Axillary Lymph Node After Neoadjuvant Chemotherapy
por: Kim, Hyunhee, et al.
Publicado: (2021)

Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory versus locally advanced breast cancers
por: Monneur, Audrey, et al.
Publicado: (2017)

Nomogram for accurate prediction of breast and axillary pathologic response after neoadjuvant chemotherapy in node positive patients with breast cancer
por: Choi, Hee Jun, et al.
Publicado: (2019)

Identification of Atypical Circulating Tumor Cells with Prognostic Value in Metastatic Breast Cancer Patients
por: Lopresti, Alexia, et al.
Publicado: (2022)

CT Radiomics for Predicting Pathological Complete Response of Axillary Lymph Nodes in Breast Cancer After Neoadjuvant Chemotherapy: A Prospective Study
por: Li, Yan-Ling, et al.
Publicado: (2023)

Sacituzumab govitecan in triple-negative breast cancer
por: de Nonneville, Alexandre, et al.
Publicado: (2022)

Higher Pathological Complete Response Rate of Less than 10 Total Axillary Lymph Nodes After Axillary Lymph Node Dissection Following Neoadjuvant Chemotherapy in Breast Cancer
por: Lee, Jeeyeon, et al.
Publicado: (2022)

Options to Determine Pathological Response of Axillary Lymph Node Metastasis after Neoadjuvant Chemotherapy in Advanced Breast Cancer
por: Murthy, Vijayashree, et al.
Publicado: (2021)

Association between tumor molecular subtype, clinical stage and axillary pathological response in breast cancer patients undergoing complete pathological remission after neoadjuvant chemotherapy: potential implications for de-escalation of axillary surgery
por: Hong, Jin, et al.
Publicado: (2021)

Response in axillary lymph nodes to neoadjuvant chemotherapy for breast cancers: correlation with breast response, pathologic features, and accuracy of radioactive seed localization
por: Clark, Beth Z., et al.
Publicado: (2023)

Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma
por: Jones, R L, et al.
Publicado: (2006)

Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients
por: Sasanpour, Pegah, et al.
Publicado: (2018)

Influences on pathologic complete response in breast cancer patients after neoadjuvant chemotherapy
por: Müller, Carolin, et al.
Publicado: (2021)

Nomogram for predicting axillary lymph node pathological response in node-positive breast cancer patients after neoadjuvant chemotherapy
por: Wang, Wenyan, et al.
Publicado: (2022)

Breast MRI and tumour biology predict axillary lymph node response to neoadjuvant chemotherapy for breast cancer
por: Al-Hattali, Samia, et al.
Publicado: (2019)

Prognostic significance of pathological complete response following neoadjuvant chemotherapy for operable breast cancer
por: KAWAJIRI, HIDEMI, et al.
Publicado: (2014)

Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
por: Santonja, Angela, et al.
Publicado: (2018)

Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
por: Nakashoji, Ayako, et al.
Publicado: (2017)

Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response
por: Resende, Uanderson, et al.
Publicado: (2019)

High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer
por: Alba, Emilio, et al.
Publicado: (2016)

Accuracy of axillary ultrasound after different neoadjuvant chemotherapy cycles in breast cancer patients
por: Ye, Bei-Bei, et al.
Publicado: (2016)

The applicability of Magseed® for targeted axillary dissection in breast cancer patients treated with neoadjuvant chemotherapy
por: Reitsamer, R., et al.
Publicado: (2021)

Prediction of axillary response after neoadjuvant chemotherapy in clinical node positive breast cancer
por: Zheng, Weizhen, et al.
Publicado: (2021)

Nomogram for predicting axillary lymph node status after neoadjuvant chemotherapy in breast cancer
por: Wang, Mengshen, et al.
Publicado: (2020)

CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response
por: Boudin, Laurys, et al.
Publicado: (2022)

Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy
por: Tanioka, M, et al.
Publicado: (2010)

Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques
por: Heil, Joerg, et al.
Publicado: (2015)

Impact of Pathologic Complete Response following Neoadjuvant Chemotherapy ± Trastuzumab in Locally Advanced Breast Cancer
por: Al-Tweigeri, Taher, et al.
Publicado: (2021)

Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review
por: de Freitas, Ana Julia Aguiar, et al.
Publicado: (2021)

Racial/Ethnic Differences and Trends in Pathologic Complete Response Following Neoadjuvant Chemotherapy for Breast Cancer
por: Ma, Sung Jun, et al.
Publicado: (2022)

Tailoring neoadjuvant chemotherapy for patients with breast cancer who have achieved pathologic complete response
por: Li, Xianjun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_b9oacoq4tk462k6u4mi1gp0nca